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Abstract
Effective mitochondria bioenergetics requires the proper functioning of various intra-
organelle dehydrogenases. By providing pyridine and flavin adenine dinucleotides to 
the electron chain, or Acyl-CoA for the reactions of the tris-carboxylic acid cycle, or the 
acylation of fatty acids to undergo β-oxidation, these dehydrogenases preside to the 
organelle production of ATP, required for a variety of cellular functions under physi-
ological conditions. The operation of the various dehydrogenases is mainly regulated 
by hormones through changes in intra-mitochondrial cation levels and ratios, namely 
Ca2+ and Mg2+. Dysregulation of specific dehydrogenases under pathological conditions 
results in marked changes in the energetic level of the organelle and ultimately the cell. 
The present review will attempt to highlight the role of the main mitochondrial dehydro-
genases and their regulation, and provide a general assessment of their dysfunction and 
associated consequences under some of the most common human pathologies.
Keywords: mitochondria, dehydrogenases, calcium, magnesium, diabetes, obesity, 
cancer
1. Introduction
The oldest reports of intracellular structures that most likely represented mitochondria date 
back to 1840s [1], whereas the association of these organelles with specific biological functions 
essential for the hosting cells can be attributed to Altman [2]. The first utilization of the term 
‘mitochondrion’ is attributed to Benda, in 1895 [3]. Regaud, in the early twentieth century, 
suggested that the organelle was constituted of protein and lipids [4], but it is not until the 
1960s through the seminal work by Palade [5] and the use of electron microscopy that the 
structure and morphology of the organelle as it is currently known was defined. Alongside 
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these studies, the utilization of various experimental approaches resulted in the identifica-
tion of a variety of enzymes and proteins localized either within the mitochondrial matrix 
or associated with the inner mitochondrial membrane or the inter-membraneous space, as 
well as the presence of mitochondrial DNA [for an historical overview see [6] and the refs. 
therein]. Because the reduplication of mitochondrial DNA occurs following the reduplica-
tion of cellular DNA, and mDNA only accounts for less than half of all the mitochondrial 
enzymes and proteins, sophisticated biological mechanisms are in place to coordinate the 
import and proper allocation of mitochondrial enzymatic components within the organelle 
following their cellular synthesis. Furthermore, mitochondria are not static organelles but 
undergo constant fusion and division (fission) to form ever changing tubular networks in 
most eukaryotic cells. These changes are important for the normal physiology of the cell, and 
may dramatically affect cell behavior under pathological conditions.
From the functional stand-point, mitochondria are regarded as the source of energy for the 
cell, in that they produce a steady flow of ATP that is utilized in a variety of cellular functions 
and signaling events. In addition to producing ATP, mitochondria play a major role in signal-
ing, cell differentiation and growth, cell cycle, cell death (apoptosis), and in the production of 
reactive oxygen species (ROS) [7].
While certain mitochondrial functions are present almost exclusively in specific cells (e.g. 
ammonia detoxification in hepatic mitochondria), ATP production represents the predomi-
nant and ubiquitous function of the organelle in all eukaryotic cells. The chemiosmotic cou-
pling of proton movement out of specific sites of the electron transport chain to their re-entry 
through the F0-F1 ATPase, with associated ATP production in a 3H+: 1ATP ratio, as proposed 
by Mitchell [8] in 1966, is now generally accepted, although some details of the process need 
further refinement. The generated ATP is then extruded in a 1ADPin: 1ATPout ratio into the cytoplasm through the adenine nucleotide translocase (AdNT), one of the most abundant 
proteins present in the mitochondrial membrane.
Despite our current understanding of the mechanisms responsible for ATP synthesis within 
the mitochondria and its extrusion across the organelle membrane, the specific role of various 
mitochondrial dehydrogenases and their regulation in modulating ATP synthesis to maintain 
a stable and viable flow of energetic ‘currency’ for the cell based on the available substrate is 
still not completely elucidated.
The present review does not have the pretense of being comprehensive in addressing the role 
and regulation of all mitochondrial dehydrogenases. Rather, it will focus on the regulation of 
some of them, and the dysregulation occurring under specific pathological conditions, which 
ultimately impacts the proper functioning of specific organs or tissues.
2. Key mitochondrial dehydrogenases and their regulation
For the purpose of this review, we will focus on the following dehydrogenases:
Glutamate dehydrogenase (EC 1.4.1.4): The presence of this enzyme in eukaryotes is essential 
for urea synthesis in the urea cycle, in that it converts glutamate to α-ketoglutarate, and 
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vice versa. However, in addition to having a very low Km for ammonia (~1 mM), at equi-
librium the reaction catalyzed by this enzyme favors ammonia and α-ketoglutarate pro-
duction. Conversion of α-ketoglutarate to glutamate does occur in brain mitochondria as a 
result of local NAD+:NADH/H+ ratio [9]. In humans, the activity of the enzyme is regulated 
through ADP-ribosylation, but also by caloric restriction or hypoglycemia, as either of the 
latter two conditions increase glutamate dehydrogenase activity to increase the amount of 
α-ketoglutarate produced. In turn, α-ketoglutarate is used to provide energy thought the cit-
ric acid cycle, ultimately generating ATP. The activity of the enzyme does not appear to be 
regulated by an increase in the levels of Ca2+ and Mg2+, which can accumulate to a significant 
extent within mitochondria under physiological conditions. On the other hand, Zn2+ has been 
reported to act as an allosteric regulator of the enzyme, together with ATP and possibly GTP.
α-ketoglutarate dehydrogenase (1.2.4.2): Also known as oxoglutarate dehydrogenase complex 
(OGDC), this enzymatic complex is known for its role in the citric acid cycle. Three different 
forms of this complex can be identified based on the specific substrate of interaction. One 
form is specific for pyruvate, a second one is specific for 2-oxoglutarate, and a third one is 
specific for branched-chain α-keto-acids. Because the same dehydrogenase subunit is utilized, 
the three forms of the complex utilized the same coenzymes: i.e. TTP, CoA, lipoate, FAD and 
NAD. Functionally, this dehydrogenase is involved in lysine degradation and tryptophan 
metabolism in addition to playing a key control point in the TCA cycle. In this contest, the 
dehydrogenase controls the level of reducing equivalents, such as NADH, generated in the 
cycle which, in turn increase the electrons flux through the mitochondrial electron transport 
chain, enhancing oxidative phosphorylation and ultimately ATP synthesis [10]. In a classic 
enzymatic inhibitory feedback, the activity of α-ketoglutarate dehydrogenase is inhibited 
by the reaction by-products succinyl-CoA and NADH, as well as by a high energy status 
(elevated ATP and NADH levels) within the cell, and by CoA-SH. Conversely, an increase in 
ADP level acts as an allosteric activator of the dehydrogenase. Calcium [10] and magnesium 
[11] ions also act as allosteric activators of the enzyme. The effects of Ca2+ and Mg2+ on the 
enzyme activity appear to be additive when the concentrations of free Mg2+ in the matrix is 
<1 mM. The presence of the divalent cations markedly decrease the Km for α-ketoglutarate from ~4–5 mM in the absence of Ca2+ and Mg2+, to 2.2 mM in the presence of Ca2+ alone, to 
0.3 mM in the presence of both cations [11]. The effect of Mg2+ is only observed in the presence 
of thiamine pyrophosphate (TPP), suggesting that the enzyme requires both TPP and Mg2+ 
for maximal activity. The presence of both cations also decreases the affinity of the dehydro-
genase for NAD+ [11]. The modulatory effect of both Ca2+ and Mg2+ are observed at concentra-
tions that are well within the range reported to occur in mitochondria for these cations under 
stimulatory conditions, e.g. by catecholamine or other hormones, thus supporting the likeli-
hood that these regulatory effects can occur under in vivo conditions.
A side product of a-ketoglutarate activity is the generation of free radicals, which can lead to 
oxidative stress if accumulating in high levels due to increased production and/or reduced 
detoxification. Due to its ability to generate free radicals, this dehydrogenase is considered 
de facto a mitochondrial redox sensor [12] in that it can modulate the rate of mitochondrial 
functioning and consequently the level of oxidative stress, thereby limiting the associated 
damage [12]. Under conditions in which the level of free radicals becomes extremely elevated, 
the enzyme can undergo a fully reversible oxidative inhibition [13]. This temporary inhibition 
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appears to occur through the reversible glutathionylation of the E2-lipoic acid domain of the 
dehydrogenase [14], thereby protecting the E2 domain, and the catalytic site of the dehydro-
genase, from damaging oxidative stress. As the flux of electrons through the electron chain 
decreases, so does the production of free radicals, optimizing the conditions for the mitochon-
drial detox systems to scavenger these toxic agents.
Isocitrate Dehydrogenase (1.1.1.42 and 1.1.1.41): This enzyme catalyzes the oxidative decarbox-
ylation of isocitrate to generate a-ketoglutarate and CO
2
 in the citric acid cycle. The reaction 
is a two-step process, supported by the conversion of NAD+ to NADH. The mitochondrial 
isoform of this enzyme, IDH3, is a heterotetramer composed by two alpha, one beta, and one 
gamma subunits (2α1β1γ) Two other isoforms (IDH1 and IDH2) of the enzyme are known 
in humans. They catalyze the same reaction in the cytosol and in peroxisomes converting 
NADP+ to NADPH in the process.
Owing to the large negative free energy change involved in the reaction, the step catalyzed by 
this dehydrogenase represents one of the irreversible reactions in the citric acid cycle. Hence, 
tight regulation is required to avoid unnecessary depletion of isocitrate. The reaction is pro-
moted by substrate availability and the presence of cofactors such as NAD+ and Mg2+ (or Mn2+), 
which both bind specific active sites on the IDH structure, and inhibited by ATP levels [15]
Succinate dehydrogenase (1.3.5.1): This enzyme participates in two key cycles within the mito-
chondrion. It is part of the respiratory complex II (whereby it is also defined as succinate-
coenzyme Q reductase) and as such is key in controlling the electron flux through the electron 
transport chain [16]. In addition, it participates in the citric acid cycle, in which it catalyzes the 
oxidation of succinate to fumarate with the reduction of ubiquinone to ubiquinol.
Structurally, the succinate dehydrogenase is composed of 2 hydrophilic and 2 hydrophobic 
subunits. The two hydrophilic subunits possess a covalently attached flavin adenine dinu-
cleotide (FAD) cofactor and the succinate binding site (subunit SdhA) and three iron–sulfur 
clusters (SdhB). The subunit SdhA provides the binding site for the oxidation of succinate. 
The two hydrophobic subunits SdhC and SdhD act as membrane anchors. Human mitochon-
dria contain 2 distinct SdhA isoforms (FpI and FpII), which form a membrane bound cyto-
chrome b complex with 1 heme b group and 1 ubiquinone binding site. More specifically, the 
ubiquinone binding site is located in an enclosure formed by SdhB, and the two hydrophobic 
subunits SdhC and SdhD. These two subunits also present one cardiolipin and one phospha-
tidylethanolamine molecule attached [17].
Functionally, the succinate-binding site in SdhA and the ubiquinone-binding site in the pocket 
formed by the three other subunits are connected by a chain of redox centers that include FAD 
and the three iron–sulfur clusters [17]. Due to its localization, the succinate dehydrogenase 
participates to both the citric acid cycle and the respiratory chain, as indicated previously. 
Electron removed from succinate during its oxidation to fumarate are transferred through the 
iron–sulfur clusters present in SdhB to the ubiquinone molecule, and ultimately to the two 
hydrophobic subunits anchoring the complex to the mitochondrial membrane. The accep-
tance of the electrons by the ubiquinone occurs in a two-step process whereby, after the first 
electron transfer, the ubiquinone is converted to a semiquinone radical species. The transfer 
of the second electron fully converts this intermediate to ubiquinol [18]. Hence, SdhA acts as 
an intermediate in the enzymatic activity of the succinate dehydrogenase complex in that: 
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1) it converts succinate to fumarate as part of the citric acid cycle while converting FAD to 
FADH
2
; 2) electrons from FADH2 are transferred to the iron–sulfur clusters of the SdhB sub-
units as part of the respiratory chain function, and 3) the electrons are ultimately transferred 
to ubiquinone Q via the hydrophobic subunits o the complex. Inhibition of the succinate-
ubiquinone activity results in the transfer of the electrons flowing through the SdhB subunit 
to O
2
, thereby generating reactive oxygen species (e.g. superoxide). Accumulation of reactive 
oxygen species stabilizes the production of HIF-1α, and facilitating its interaction with HIF-1b 
to form a critical heterodimeric complex that induces the expression of anti-apoptotic genes 
but also tumor-causing genes (see section 3 for further details). Under conditions in which 
succinate dehydrogenase activity is inhibited, succinate accumulates within the mitochon-
dria and then diffuses into the cytoplasm where it inhibits the physiological hydroxylation 
of HIF-1α in the cytosol by prolyl-hydroxylase (PHD). Inhibition of HIF-1a hydroxylation 
works in conjunction with the accumulation of reactive oxygen species occurring through the 
succinate dehydrogenase complex to stabilize HIF-1a and promote the formation of a stable 
and active HIF complex that promotes the expression of tumor-inducing genes [19]. Because 
PHD activity requires oxygen, α-ketoglutarate as substrates, and ferrous iron and ascorbate 
as co-factors, increasing α-ketoglutarate levels could represents a viable therapeutic approach 
to limit tumor development and growth under SDH deficiency.
Pyruvate dehydrogenase (1.2.4.1): This enzyme is the first component of the pyruvate dehy-
drogenase complex (PDC), which is responsible for transforming pyruvate to acetyl-CoA via 
pyruvate decarboxylation. The Acetyl-CoA generated by the reaction then enters the citric 
acid cycle, contributing to cell respiration. As a result, pyruvate dehydrogenase links glycoly-
sis to the citric acid cycle and the release of energy via NADH. The complex is constituted 
by the pyruvate dehydrogenase (E1) component, a dihydrolipoamide acetyltransferase (E2) 
component, a pyruvate dehydrogenase kinase (PDK) and a pyruvate dehydrogenase phos-
phatase. The reaction operated by E1 uses thiamine pyrophosphate (TPP) as a required cofac-
tor, and it is considered to be the rate-limiting step for the whole pyruvate dehydrogenase 
complex (PDHc) activity. Phosphorylation of E1 by PDK inactivates E1 and consequently 
the whole complex. Pyruvate is a natural inhibitor of PDK, thereby resulting in a higher 
level of active, unphosphorylated PDH [20]. Alternatively, the phosphorylation state of E1 
is reversed by the activity of pyruvate dehydrogenase phosphatase, which is stimulated by 
insulin, phospho-enol-pyruvate, and AMP, and competitively inhibited by ATP, NADH, and 
Acetyl-CoA. Physiological fluctuations in mitochondrial Ca2+ and Mg2+ levels, as observed 
following insulin stimulation, also stimulate the phosphatase activity, maintaining E1 in the 
active state [20].
3. Mitochondrial dehydrogenases and cancer
Cancer cells are characterized by increased glycolytic ATP production as a result of decreased 
mitochondria effectiveness. Inhibition (or decreased activity) of the citric acid cycle is con-
sidered to be one of the main causes forcing the cells to generate ATP through anaerobic 
glycolysis [21]. This reprogramming results from oncogene activation or inhibition of tumor 
suppressors [21]. Consistent with this observation, inhibition of glycolysis by dichloroacetate, 
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a pyruvate inhibitor, shifts cell metabolism back to oxidative phosphorylation, at least to a 
certain extent [22]. This metabolic reprogramming is considered to be necessary to meet the 
needs of the rapid proliferative rate exhibited by cancer cells. Two key bioenergetics param-
eters resulting from the mentioned metabolic reprogramming are anaerobic glycolysis, with 
associated extracellular acidification, and mitochondrial respiration.
Altered functioning of any of the mentioned dehydrogenases has been observed in different 
cancer cells, and specific correlations have been observed and documented. For example, glu-
tamate dehydrogenase can be considered as biomarkers for cancer cell growth [23]. Similarly, 
defects in isocitrate dehydrogenase [24], a-ketoglutarate dehydrogenase [25] succinate dehy-
drogenase [26], and pyruvate dehydrogenase [27] have all been reported in a variety of cancer 
cells, and associated with the metabolic reprogramming these cells undergo. The picture that 
emerges is that many cancer cells are hypoxic and therefore metabolize lactate to pyruvate to 
generate ATP [28]. The occurrence of hypoxia results in the activation of hypoxia-inducible 
factor 1 (HIF-1) heterodimeric DNA-binding complex and pro-neoplastic genes in tumor cells. 
HIF-1α is continuously synthesized and degraded, with a half-life of ~6 min under normoxic 
conditions. Under hypoxia conditions, however, the rate of HIF-1α degradation decreases 
significantly as a result of prolyl hydroxylation and proteosomal degradation suppression by 
accumulating succinate and increasing ROS formation and enzyme modification. As a result, 
HIF-1 heterodimer accumulates, and translocated to the nucleus of the cells where it activates 
genes responsible for increased glucose uptake (mostly GLUT1) and lactate production. At 
the same time, the increase in succinate levels further depresses mitochondrial respiration, 
with increased routing of O
2
 towards ROS formation. In addition to upregulating the glucose 
transporter, HIF-1 promotes the expression of various glycolytic enzymes as well as PDK-
1, the kinase that phosphorylates and inactivates the pyruvate dehydrogenase subunit E1. 
Inactivation of this dehydrogenase prevents pyruvate entry into the TCA cycle, thus down-
regulating mitochondria respiration [29].
Another pathway involved in modulating mitochondria activity and responsiveness in cancer 
cells is the one tapping onto peroxisome proliferator-activated receptor gamma co-activator 
1alpha (PGC1α). This pathway has been observed to be overexpressed in some subsets of mela-
nomas in which it activates mitochondrial oxidative phosphorylation and TCA-cycle specific 
genes for the metabolic needs of the cancer cells [30]. In addition, PGC1α promotes the expres-
sion of genes involved in de novo lipogenesis and in the pentose phosphate pathway, increasing 
NADPH production for fatty acid synthesis purposes [30]. While genes involved in oxidative 
phosphorylation and TCA cycle are located in mitochondria, those involved in the pentose 
phosphate pathway and fatty acid synthesis are located in the cytoplasm of the cell. How exactly 
Acyl-CoA generated within the mitochondrion through aerobic glycolysis (pyruvate dehydro-
genase) is utilized to enhance fatty acid synthesis is not completely understood. Experimental 
evidence would suggest that PGC1α may do so by inducing the expression of genes responsible 
for converting citrate back to oxaloacetate and Acyl-CoA [30]. Irrespective of the precise mecha-
nisms involved in the metabolic reprogramming of cancer cells, PGC1α-positive cancer cells 
are particular sensitive to pharmacological (e.g. metformin) or chemical (e.g. rotenone or FCCP) 
inhibitors of oxidative phosphorylation, in stark contrast to PGC1α-negative cancer cells, which 
are more sensitive to anti-glycolytic agents (e.g. 2-deoxyglucose, or 2-DG).
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Mitochondrial ROS and Cancer: Reactive oxygen species (ROS) are by-products of mitochon-
drial electron transport chain, generated by the incomplete reduction of oxygen as electrons 
flow from one complex to the next. Under physiological conditions, 1–2% of the molecular 
oxygen utilized by the mitochondria is converted to ROS [31]. Reactive oxygen species are 
highly reactive molecules, which act as oxidants removing electrons from DNA, proteins, and 
lipids. While ROS can be generated at the level of the plasma membrane (NADPH oxidase) 
and the endoplasmic reticulum of cell abundant in cytochrome activity (e.g. hepatocytes), 
the main intracellular source of ROS in most cells is indeed represented by mitochondria. In 
particular, O
2
− is the main byproduct of oxidative phosphorylation, and acts as precursor of 
other ROS products such as hydrogen peroxide (H
2
O
2
) and hydroxyl radical (OH−). Due to 
its negative charge, O
2
− cannot diffuse across biological membrane. However, evidence sug-
gests that it can cross the mitochondrial membrane and diffuse into the cytoplasm through 
VDAC and other not-yet identified mitochondrial channels [32]. Either in the mitochondria 
or in the cytoplasm superoxide dismutases convert O
2
− to H
2
O
2
, which can now diffuse freely 
across membranes. H
2
O
2
 is highly reactive towards cysteine residues, and this reactivity is 
further enhanced in the presence of O
2
− and iron or other transition metals (Fenton reaction or 
Haber-Weiss reaction), generating the more reactive but short-lived OH−, which interacts with 
any surrounding macromolecule, including proteins, lipids, nucleic acids, and carbohydrates 
[33]. Interaction of ROS with surrounding macromolecules may result in damage of biological 
membrane, enzyme inactivation, and genotoxicity. High levels of ROS can induce apoptosis 
and cell death whereas low levels of ROS can act as signaling molecules, and either path can 
results in tumor initiation and progression.
Cellular DNA and mitochondrial DNA are both highly susceptible to ROS-induced damage. 
This susceptibility is more pronounced for mitochondrial DNA, due to the close proximity 
to the electron transport chain where ROS are generated, the absence of protective histones, 
and the limited DNA repair capability. As a result, the mutation rate of mitochondrial DNA is 
two orders of magnitude higher than that of nuclear DNA. Consistent with this notion, muta-
tions in mitochondrial DNA - in particular mutations of oxidative phosphorylation enzymes 
- have been observed in many neoplastic cells (see previous section), in which they result in 
oxidative phosphorylation dysfunction, increased ROS formation, and energetic shift towards 
anaerobic glycolysis.
The role of ROs as signaling molecules in cell proliferation, differentiation, migration, meta-
static colonization, and gene transcription is now fairly well recognized. The ability of ROS to 
act as signaling molecules depends on the presence of redox-sensitive proteins that operate 
as ‘ROS sensors’. In most cases, the sensing ability lies in the reversible oxidation of sulfhy-
dryl groups in specific cysteine residues by H
2
O
2
 or other ROS, resulting in the inhibition of 
that particular protein. For the most part, this inhibition is transient in that the cell possesses 
scavenging mechanisms (e.g. glutathione) to reduce the sulfhydryl groups back to the original 
state, thus restoring the protein’s activity or signaling properties [34].
The levels of ROS produced by tumor cells are usually higher than those present in normal 
cells, and they results in DNA damage but also in increased tumorigenesis and metastasis via 
direct activation of signaling pathways [35]. Two signaling pathways activated by ROS are MAP 
Kinase and phosphoinositide 3-kinase, which both control cell survival and proliferation. The 
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upregulation of these pathways increases the expression of oncogenes and proteins involved 
in metastasis (e.g. matrix metalloproteinases) and in epithelial to mesenchymal transition [36]. 
Of note, oncogene activation has been reported to enhance mitochondrial ROS production, and 
ROS generation appears to be required for oncogene-mediated cell transformation [37].
4. Mitochondrial dehydrogenases under diabetic conditions
A vast body of literature covers the functional modifications of mitochondria under diabetic 
conditions. Because cardiovascular insults remain the leading cause of death for diabetic 
patients [38], most of the attention has been focused on the modifications occurring in cardiac 
mitochondria to provide a better rationale for the morphological and functional modifications 
observed in diabetic hearts. Further, the incidence and severity of cardiovascular complica-
tions are markedly increased in both male and female diabetic patients, with the latter exhibit-
ing a greater incidence than the diabetic male counterparts [39].
In humans, our understanding of the disease is complicated by the presence of two pathologi-
cal conditions: diabetes type 1, in which insulin production is lacking, and diabetes type 2, in 
which insulin is still produced, sometimes to a greater extent than under normal conditions, 
and yet it is not functionally efficient in controlling the glycemic state of the patient. An addi-
tional confounding parameter is that to a large extent type 2 diabetic patients are overweight 
or obese, with an altered lipid status both in serum and within tissues (lipotoxicity).
This variety of conditions is also reflected in the heterogeneity of animal experimental mod-
els utilized to investigate the disease. Also here, models of type 1 diabetes are conceptually 
simpler in that animals are injected with agents that damage pancreatic beta-cells and abolish 
insulin secretion, fully mimicking the human condition. Models for type 2 diabetes are more 
heterogeneous, spanning from genetically conditioned animals (KO animals for specific pro-
teins, receptors, or signaling molecules) to genetically inbred animals (e.g. Koletsky rats), to 
animals that develop diabetes spontaneously, to animals fed assorted high fat diets with or 
without sucrose, and injected with subliminal doses of beta-cell damaging agents that limit 
but not completely abolish the endogenous production of insulin, or treated with various 
oral antidiabetic agents [40]. Because of this plethora of models, it is not simple to determine 
to which extent modifications of mitochondrial dehydrogenase are a primary or secondary 
insult in the pathogenesis of the diabetic condition and its complications.
The development of diabetic cardiomyopathy has been etiologically attributed to several fac-
tors including metabolic [41], biochemical [42] and ultra-structural [43] modifications within 
the cardiac myocytes. Scrutiny of mitochondrial function in cardiac mitochondria from strep-
tozotocin-treated rats has shown a decline in respiration and oxygen consumption, more pro-
nounced for state 3 than state 4, which translates into a decrease in ATP production [44]. This 
energy deficiency has been considered a key factor in the development of diabetes-related 
cardiac dysfunctions, although changes in cardiac microvasculature [45], metabolic and hor-
monal disturbances [46] and concurring hyperglycemia [47] can certainly act as co-factors. 
Combining defective mitochondrial respiration with increased ROS formation, studies from 
our laboratory have indicated that succinate dehydrogenase [48] and pyruvate dehydroge-
nase [49] are highly sensitive to ROS-induced damage, forming stable, non-functional adducts 
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within the mitochondrion of streptozotocin-treated rats. As mentioned in the previous sec-
tion, the consequences of this dysfunction are three-fold: 1) the inability of the electron trans-
port chain to operate properly is compromised, resulting in decreased ATP production; 2) the 
production of ROS is enhanced, further damaging macromolecules within the mitochondrion 
and its surroundings, and 3) forcing the cardiac myocytes to depend on glycolysis to produce 
ATP. Interestingly, these changes were observed predominantly in cardiac and liver tissue but 
not in the kidney of the diabetic animals [49], rising the intriguing question of which protec-
tive mechanism(s) may operate in the latter organ under diabetic conditions.
5. Mitochondrial dysfunction in obesity
The term obesity refers to a condition in which the amount of fat tissue in the body is increased 
to an excessive degree (i.e. more than 25% in body weight in men and more than 30% in women). 
The incidence of obesity or just overweight has been on the rising for the last several decades, and 
currently affects anywhere between 35 and 45% of the population, in developed and developing 
countries [50]. Obesity is the sixth most important risk factor, and the number of affected indi-
viduals has reached 2.1 billion worldwide, including 10% of all children. The main complications 
include particular forms of cancer (e.g. colon and breast cancer, in particular), type 2 diabetes 
mellitus, cardiovascular pathologies including stroke, and musculoskeletal dysfunctions, with a 
prohibitive price tag in terms of healthcare costs, morbidity and mortality [51]. Several reviews 
have addressed the changes in mitochondria functioning in obesity, and we refer to them for an 
in-depth understanding of the changes occurring in the organelle [52–53]. The emerging picture 
indicates that cardiac cells, adipocytes, skeletal muscle cells, beta-cells, liver cells and others 
are affected to a varying degree by lipotoxicity [54], which also affects mitochondria operation. 
Whether the dysfunction strictly depends on the abnormal presence of fatty acid in the cells and 
the biological membrane of the organelle, or other not-yet identified factors remains undefined. 
The most common mitochondrial dysfunctions associated with obesity have been identified in 
an abnormally low number of mitochondria with altered morphology, decreased expression 
of the F1-ATPase subunit, with consequent low ATP generation [53], higher expression of the 
uncoupling protein 2 (UCP2) [52] with associated increased production of O
2
−, ROS in general, 
and apoptosis [52]. At the same time, the abnormal presence of fatty acids and ceramide within 
the cell activate specific signaling that further impair the tissue response to insulin [53]. Due to 
the decline in number and the altered morphology of mitochondria, an unanswered question 
remains as to whether these modifications are secondary to intrinsic defects in mitochondrial 
dehydrogenases that link electron transport chain to TCA cycle and/or to proper ATP synthesis, 
or whether defects in mitochondria enzymes are consequence of defective synthesis of key com-
ponents within the cell nucleus and defective import into already altered organelles.
6. Conclusions
The picture we have attempted to draw in the present review moves from the important role 
specific mitochondrial dehydrogenases play in cell metabolism. Under conditions in which 
metabolic reprogramming occurs (i.e. cancer, diabetes, obesity), cells move away from efficient 
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mitochondrial bioenergetics and come to rely on glycolysis for ATP generation purposes. This 
metabolic shift has the unintended consequence of increasing reactive oxygen species produc-
tion, which further disrupt cell metabolism and activate genes and oncogenes through spe-
cific signaling pathways and nuclear transcription factors (HIF-1α, MAPKs, PI3K). Current 
and future lines of research aim at better understanding the signaling and metabolic routes 
connecting mitochondria to cell functions in the attempt to possibly recondition metabolism 
and energy production of target cell and mitochondria.
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